Impact of linker length on the activity of PROTACs.

Molecular bioSystems (2010-10-06)
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, Hyeong-Jun Han, Hyosung Lee, Hollie Swanson, Kyung-Bo Kim
摘要

Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations, a small molecule-based novel technology termed "PROteolysis TArgeting ChimeraS (PROTACs)" has been developed, targeting proteins for degradation at the post-translational level. Despite the promising potential of PROTACs to serve as molecular probes of complex signaling pathways, their design has not been generalized for broad application. Here, we present the first generalized approach for PROTAC design by fine-tuning the distance between the two participating partner proteins, the E3 ubiquitin ligase and the target protein. As such, we took a chemical approach to create estrogen receptor (ER)-α targeting PROTACs with varying linker lengths and the loss of the ER in cultured cells was monitored via western blot and fluorometric analyses. We found a significant effect of chain length on PROTAC efficacy, and, in this case, the optimum distance between the E3 recognition motif and the ligand was a 16 atom chain length. The information gathered from this experiment may offer a generalizable PROTAC design strategy to further the expansion of the PROTAC toolbox, opening new possibilities for the broad application of the PROTAC strategy in the study of multiple signaling pathways.

材料
货号
品牌
产品描述

Sigma-Aldrich
(S,R,S)-AHPC-pyrimidine-piperazine-PEG1-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-pyridine-PEG1-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-pyrimidine-piperazine-PEG1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
C5 Lenalidomide-PEG6-Butyl NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG2-butyl CO2H, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-C3-CO2H, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-methylamino-PEG1-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-PEG2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-CO2H, 95%
Sigma-Aldrich
Pomalidomide-pyridine-PEG1-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-pyridine-PEG1-piperazine hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG1-CO2H, ≥95%
Sigma-Aldrich
Pomalidomide-benzyl-piperazine hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-benzyl-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-benzyl-piperazine hydrochloride
Sigma-Aldrich
Pomalidomide-C3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG4-CO2H
Sigma-Aldrich
(S,R,S)-AHPC-PEG5-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-piperazine-pyridine-alkyne-NH2 hydrochloride
Sigma-Aldrich
Pomalidomide-PEG6-NH2 hydrochloride, ≥98%
Sigma-Aldrich
Pomalidomide-PEG1-Alkyne, ≥98%
Sigma-Aldrich
(S,R,S)-AHPC-C6-PEG3-butyl chloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG6-Azide, ≥95%
Sigma-Aldrich
Pomalidomide-C9-CO2H, ≥95%
Sigma-Aldrich
Pomalidomide-PEG4-NH2 hydrochloride, ≥95%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。